Литература. 
Фармакотерапия остеопороза. 
Применение препарата Тевабон

1. Аудит состояния проблемы остеопороза в странах Восточной Европы и Центральной Азии, 2010. Prepared by International Osteoporosis Foundation. с.45−51.

2. Ершова О. Б. Бисфосфонаты в терапии остеопороза. Акцент на алендронат. РМЖ. Ревматология. 29 октября 2008 г, том 16, № 24, с.1626−1629.

3. Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. Под ред. Лесняк О. М., Беневоленской Л. И., 2-е изд., перераб. и доп. ГЕОТАР-Медиа. с. 261.

4. Шварц Г. Я. Алендронат натрий (Теванат): современный эффективный препарат для лечения остеопороза. // РМЖ — 2010. — т. 18. № 6 с. 393−399.

5. Шварц Г. Я. Тевабон — новый комбинированный препарат для лечения остеопороза. // РМЖ — 2011. — т. 19. № 10 с. 623−631.

6. Шварц Г. Я. Современная комбинированная фармакотерапия остеопороза. // РМЖ — 2011. — т. 19. № 13 с. 842−845.

7. Russell RGG, Watts NB, Ebetino FH, Rogers MJ.: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.// Osteoporosis International, 2008, Vol. 19, pp. 733−759.

8. Белая Ж. Е., Рожинская Л. Я., Сосунова Н. В. Роль факторов риска в диагностике остеопороза и принятии решения о назначениии терапии. Эффективность БФ в лечении остеопороза.// РМЖ., 2009, 17, № 10.

9. Plotkin LI, Manolagas SC, Bellido T.: Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclast from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs.// J. Bone, 2006, Vol. 39, pp. 443−452.

10. Liberman UA, et.al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis.// New England J. Medicine, 1995, Vol. 333, pp. 1437−1443.

11. Black DM, et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.// J. Lancet, 1996, Vol. 348, pp. 1535−1541.

12. Cummings SR, et.al.: Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures.// JAMA, 1998, Vol. 208, pp. 2077;2082.

13. Ensrud KE, et.al.: Treatment with alendronate prevents fractures in women at highest risk.// Arch Int Med, 1997, Vol. 157, pp. 2617−2624.

14. Bone HG, et.al.:Ten years experience with alendronate for osteoporosis in postmenopausal women.// New England J. Medicine, 2004, Vol. 350, pp. 1189−1199.

15. Recker RR, et.al.: Normal bone histomorphometry and 3D microarchitecture after 10 years of alendronate treatment of postmenopausal women.// J. Bone Mineral Res, 19 Suppl 1, s 45.

16. Rizzoli R, et.al.: Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.// J. Bone Miner. Res., 2002, Vol. 17, pp. 1988;1996.

17. Olszynski WP, Davison KS, Ioannidis G et al. Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study. Osteoporos Int. 2006;17(2):217−24.

18. Rekeneire N, et.al.: Is a fall just a fall: correlates of falling in healthy older persons. The Health, aging and body composition study. J. Am Geriatr Soc, 2003, Vol. 51, pp. 841−846.

19. Nevitt MC, et.al.: Risk factors for recurrent nonsyncopal falls. A prospective study. JAMA, 1989, Vol. 261, pp. 2663−2668.

20. Boland R. Role of vitamin D in skeletal muscle function. Endocr Rev 1986; 784:434−448.

21. Bischoff HA, Borchers M, Gudat F, Duermueller U, Theiler R, Stahelin HB, Dick W. In situ detection of 1,25-dihydroxyvitamin D receptor in human skeletal muscle tissue. Histochem 2001; 33:19−24.

22. Bischoff HA, Stahelin HB, Urscheler N, Ehrsam R, Vontheim R, Perrig-Chiello P, Tyndall A, Theiler R. Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 1999; 80:54−58.

23. Dukas L, Schacht E, Bischoff HA. Better functional mobility in community dwelling elderly is related to Dhormone serum levels and to a daily calcium intake. Accepted for publication in Journal on Nutrition, Health and Aging 2005.

24. Verhaar HJJ, Samson MM, Jansen PAF, de Vreede PL, Manten JW, Duursma SA. Muscle strength, functional mobility and vitamin D in older women. Aging Clin Exp Res 2000; 12:455−460.

25. Yamato H, Okazaki R, Ishii T, Ogata E, Sato T, Kumegawa M, Akaogi K, Taniguchi N, Matsumoto T. Effect of 24R, 25-dihydroxyvitamin D3 on the formation and function of osteoclastic cells. Calcif Tissue Int 1993; 52:255−260.

26. Lau KHW, Baylink DJ. Treatment of 1,25(OH)2D3(Dhormone) deficiency/resistance with D-hormone and analogs. Osteologie 2001; 10:28−39.

27. Schacht E. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. Calcif Tissue Int 1999; 65:317−327.

28. Richy F., Ethgen O., Bruyere O. et al. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004 Apr;15(4):301−10.

29. Papadimitropoulos et al. Meta-Analisis of the Efficacy of Vitamin D Treatment in Preventing Osteoporosis in Postmenopausal Woman. Endocrine Rewiews 23 (4), 2002: 560 — 569.

30. Richy F. et al. Differential effects of D-gormon analogs and native vitamin D on the risk of falls: a comparative meta-analysis. Calcif. Tissue Int. 2008;82(2):102−7.

31. Ducas L. et al. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. Osteoporosis Int. 2005. 16(2):198−203.

32. Breuil V, Cosman F, Stein L, Horbert W, Nieves J, Shen V, Lindsay R, Dempster DW. Human osteoclast formation and activity in vitiv: effects of alendronate. J Bone Miner Res 1998; 13:1721−1729.

33. Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990: 5:31−40.

34. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19:80−100.

35. Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariec-tomized rat model of osteoporosis: distinct action from estrogen. J Bone Miner Res 2000; 15:770−774.

36. Shibata T, Shiraishi A, Sato T, Masaki T, Masuda A, Hishiya A, Ishikura N, Higashi S, Uchida Y, Saito MO, Ito M, Ogata E, Watanabe K, Ikeda K. Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res 2002; 17:622−629.

37. Reszka AA, Pun S, Rodan GA, Freedman LP, Kimmel DB. Bone anabolic effects of l, 25(OH)2 Vitamin D3 are detected only in the presence of a powerful antiresorp-tive. J Bone Miner Res 2004; 19. S483.

38. Ito M, Azuma Y, Takagi H, Komoriya K, Ohta T, Kawaguchi H. Curative effect of combined treatment with alendronate and la-Hydroxyvitamin D3 on bone loss by ovariectomy in aged rats. Jpn J Pharmacol 2002; 89:255−266.

39. Ringe J.D. et al. Superiority of combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int. 2007; 27: 425−434.

40. Masud T. et al. Effects of cyclical etidronatecombined with calcitriol versuscyclical ethidronate aloneon spine and femoral neckbone mineral density in postmenopausal osteoporotic women.Ann.Rheum.Dis.1998;57:346−349.

41. Ones K., Schacht E., Dukas L., Caglar N. Effecrs of Comdinet Treatment with Alendronate and Alfacalcidol on Bone Mineral Density and Bone Turnover in Postmenopausal Osteoporosis: A two-years, randomized, multiarm, controlled trial. The Internet Jornal of Epidemiology 2007; Vol 4, Number 1.

42. Frediani В, Allegri A, Bisogno S, Marcolongo R. Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis. Two years of continuous treatment. Clin Drug Invest 1998; 15:235−244.

43. Kataxaki E, Koulouris G, Marketos G, Fragakis N, Georgiadis AE. Combined treatment of alendronate plus aiphacalcidol (One-Alpha* LEO Pharma0) on bone mass in postmenopausal osteoporosis. Calcif Tissue Int 2004; 74: S87-S88.

44. Malavolta N, Zanardi M, Veronesi M, Ripamonti C, Gnudi S. Calcitriol and alendronate combination treatment in menopausal women with low bone mass. Int J Tissue React 1999; 21:51−59.

45. Barone A. et al. Secondary Hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J.Am.Geriatr.Soc. 2007;55(5):752−7.

46. Erben RG, Mosekilde L, Thomsen JS, Weber K, Stahr K, Leyshon A, Smith SY, Phipps R. Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and la, 25-dihydroxyvitamin D3. J Bone Miner Res 2002; 17:1498−1511.

47. Nishikawa T, Ogawa S, Kogita K, Manabe N, Katsumata T, Nakamura K, Kawaguchi H. Additive effects of combined treatment with etidronate and alfacalcidol on bone mass and mechanical properties in ovariectomized rats. Bone 2000; 27:647−654.

48. Reszka AA, Pun S, Rodan GA, Freedman LP, Kimmel DB. Bone anabolic effects of l, 25(OH)2 Vitamin D3 are detected only in the presence of a powerful antiresorp-tive. J Bone Miner Res 2004; 19. S483.